Pharmacogenomic study of heart failure and candesartan response from the CHARM programme.

ABSTRACT:

Aims

The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme consisted of three parallel, randomized, double-blind clinical trials comparing candesartan with placebo in patients with heart failure (HF) categorized according to left ventricular ejection fraction and tolerability to an angiotensin-converting enzyme inhibitor. We conducted a pharmacogenomic study of the CHARM trials with the objective of identifying genetic predictors of HF progression and of the efficacy and safety of treatment with candesartan.

Methods

We performed genome-wide association studies in 2727 patients of European ancestry from CHARM-Overall and stratified by CHARM study according to preserved and reduced ejection fraction and according to assignment to

SUBMITTER: Dube MP 

PROVIDER: S-EPMC9715825 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature